These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26458436)

  • 1. [Diagnosis of MDS: morphology, chromosome abnormalities and genetic mutations].
    Hata T
    Rinsho Ketsueki; 2015 Oct; 56(10):1978-84. PubMed ID: 26458436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor].
    Borjas-Gutiérrez C; Domínguez-Cruz MD; González-García JR
    Rev Med Inst Mex Seguro Soc; 2017; 55(4):481-489. PubMed ID: 28591503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
    AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
    Wall M
    Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes.
    Vallespí T; Imbert M; Mecucci C; Preudhomme C; Fenaux P
    Haematologica; 1998 Mar; 83(3):258-75. PubMed ID: 9573680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
    Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathophysiology of MDS: genomic aberrations].
    Ichikawa M
    Rinsho Ketsueki; 2016; 57(10):1972-1979. PubMed ID: 27725595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan.
    Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
    Leukemia; 1993 Apr; 7(4):499-508. PubMed ID: 8464227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Morphologic diagnosis of myelodysplastic syndromes].
    Matsuda A
    Rinsho Ketsueki; 2017; 58(4):336-346. PubMed ID: 28484164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
    Ganguly BB; Banerjee D; Agarwal MB
    Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphology, cytogenetics and classification of MDS.
    Giagounidis A; Haase D
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):337-53. PubMed ID: 24507811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular international prognostic scoring system for myelodysplastic syndromes].
    Nagata Y
    Rinsho Ketsueki; 2023; 64(5):355-368. PubMed ID: 37271526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetics in myelodysplastic syndromes.
    Haferlach T
    Leuk Res; 2012 Dec; 36(12):1459-62. PubMed ID: 22986016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
    Mecucci C
    Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genetic basis and expanding role of molecular analysis in the diagnosis, prognosis, and therapeutic design for myelodysplastic syndromes.
    Nybakken GE; Bagg A
    J Mol Diagn; 2014 Mar; 16(2):145-58. PubMed ID: 24457119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic abnormalities and pathophysiology of MDS.
    Hosono N
    Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R
    Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.